-Christophe Sola, Professor, University Paris-Sud, R&D and production consultant, founding associate
-Michel K. Gomgnimbou, Assistant Professor and Scientist, Public Health, Centre Muraz, Bobo-Dioulasso, Burkina Faso, founding associate
-Guislaine Refrégier, Assistant Professor, University Paris-Sud, Financial Head, founding associate
-Pasquale Cutolo, PhD Student, INSERM, Paris, CEO, founding associate
-Michel K. Gomgnimbou, associate, President
-Boubacar Sanou, associate, CEO
-Clément Ripoll, associate
Beamedex® is especially interested in post-genomic era integrated genotyping tools by detection of Single Nucleotide Polymorphisms (SNPs) or Clustered regularly interspersed palindromic repeats (CRISPR)-based loci, for characterization of Infectious Diseases agents and for Pharmacogenomics.
A public genotyping plateform was first created in 2007 to genotype pathogenic bacteria such as those of Mycobacterium tuberculosis, Salmonella enterica diseases (human and animal infection) and is currently hosted by CNRS. It used molecular hybridization on biochips in suspension, on polystyrene/magnetic microspheres with probes hybridizing the CRISPR loci or SNPs, of these bacterial species. The Beamedex® company started to produce reagents in 2015 and provides highest available grade of coupled-microspheres to run our/your assays on Luminex® devices.
The CRISPR loci (Clustured Regularly Interspersed Short Palindromic Repeats) are genetic markers that allow identification and genotyping of many pathogenic bacteria. CRISPRs were characterized at the RIVM (Netherlands) under the name of« Direct Repeat locus » in Mycobacterium tuberculosis, the agent of tuberculosis. It was used to create the « spoligotyping » technique. CRISPR loci are present in 100% of Archaea and 60% of bacteria and are constituted by conserved sequence regions (the repeats) and variable sequences (the spacers). It has some physiological roles such as anti-phage or anti-plasmids "immunological" defence and it is in association with Cas (CRISPR-associated) enzymes - in particular Cas9- for genome engineering.
CRISPR typing allows to get a fine taxonomical characterization of bacterial species, both intra-specific and bio-geographic, for molecular epidemiological and/or populations structure studies (outbreak tracing).
The numerical format obtained (43 or 68-Plex for Mycobacterium tuberculosis, 72-Plex for Salmonella enterica serovar typhimurium is well-adapted for inter-laboratory comparisons).
The 59-Plex TB-SPRINT assay is the first proprietary Beamedex® assay. It was invented and developed by Michel Gomgnimbou. This method provided a new paradigm in MDR-TB control and personalized medicine. It is the first technique of that kind that simultaneously deliver results for the community and for the patient, a new paradigm in TB control. It can give you some clues to MDR-TB transmission, it will also through screening lower the amount of NGS you may want to run, after VNTR, Spoligotyping or IS6110-RFLP if you still are an addict of old-fashion fingerprinting !
The 50-Plex TB-SNPID is another MagPix® designed assay developed by the Royal Tropical Institute research team in Amsterdam (S. Sengstake, I. Bergval, R. Anthony). This assay provides, based on the MLPA principle, the most exhaustive SNP, RD and drug-resistance SNP mutations panel of information you could get for a reasonable price on one sample in a single experiment !
Large databases and data-mining methods at a later stage allow to transform raw data into information-rich medical knowledge.